Clinical Trial: Phase 1b, Open-label Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associated Periodic Syndrome (CAPS)

U.S., Nov. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07247266) titled 'Phase 1b, Open-label Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associated Periodic Syndrome (CAPS)' on Nov. 18.

Brief Summary: This study will evaluate the efficacy, safety, tolerability and pharmacokinetics of JTE-162 administered once daily for 2 weeks in subjects with cryopyrin-associated periodic syndrome (CAPS)

Study Start Date: Dec., 2025

Study Type: INTERVENTIONAL

Condition: Cryopyrin-associated Periodic Syndromes (CAPS)

Intervention: DRUG: JTE-162

Tablets containing JTE-162

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Akros Pharma Inc.

Publish...